GLP-1 Analogues Market Size, Share & Forecast Report, 2026-2034 REPORT DETAILS GLP-1 Analogues Market Summary The global GLP-1 analogues market size was valued at USD 56.62 billion in 2025
Liraglutide 3mg This agent is administered subcutaneously every day
Obese individuals are at risk of developing various chronic diseases, such as diabetes mellitus, hypertension, cancer, and neurological disorders, which could be severely impacted by the buildup of excess body fat (WHO, 2021)
Sample Size: 125,474 adults T2DM (61.0% of total sample, n = 76,524) 98.6% (n = 75,434) using GLP-1s as antidiabetic medications 1.4% (n = 1,090) using GLP-1s as antiobesity medications Without T2DM (39.0% of total sample, n = 48,950) 61.8% (n = 30,236) using GLP-1s off-label as antidiabetic medications 38.2% (n = 18,714) using GLP-1s specifically for weight management Data Source: Truveta Data Aggregated electronic health record (EHR) data from 30 U.S
Semaglutide Semaglutide, the active ingredient in Brightmeds treatment, is a GLP-1 receptor agonist that mimics a natural hormone in your body
